Plasma concentration of platelet-derived microparticles is related to painful vaso-occlusive phenotype severity in sickle cell anemia

Danitza Nebor, Andre Bowers, Philippe Connes, Marie-Dominique Hardy-Dessources, Jennifer Knight-Madden, Vanessa Cumming, Marvin Reid, Marc Romana, Danitza Nebor, Andre Bowers, Philippe Connes, Marie-Dominique Hardy-Dessources, Jennifer Knight-Madden, Vanessa Cumming, Marvin Reid, Marc Romana

Abstract

High plasma level of microparticles (MPs) deriving mainly from erythrocytes and platelets has been detected in sickle cell anemia (SCA) patients. Flow cytometry was used to determine the concentration of MPs in two groups of SCA patients exhibiting marked differences in painful vaso-occlusive crisis rates [a non-severe group (n = 17) and a severe group (n = 12)], and in a control group composed of healthy subjects (n = 20). A 3- to 4-fold increase of total MP plasma concentration was detected in SCA patients. Higher platelet-derived MPs concentration was detected in the severe SCA group while erythrocyte-derived MPs concentration was increased in the non-severe SCA patient group only. Our results suggest that plasma concentration of MPs shed by platelets is a biomarker of the vaso-occlusive phenotype-related severity.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Representative flow cytometry analysis for…
Figure 1. Representative flow cytometry analysis for quantifying microparticles originated from red blood cells and platelets.
Figure 1A: Acquisition gate set up using the fluorescent microbeads size of the megamix kit according to the manufacturer instructions. Figure 1B: negative control using isotypic control-PE and annexin V-FITC in EDTA buffer. Figure 1C: double fluorescence plots demonstrating MPs originated from RBCs. Figure 1D. double fluorescence plots demonstrating MPs originated from platelets.
Figure 2. Comparison of MPs concentration between…
Figure 2. Comparison of MPs concentration between control group and SCA patients groups.
Figure 2A: Total MPs. Figure 2B: Platelet-derived MPs. Figure 2C: Erythrocyte-derived MPs.

References

    1. Stuart MJ, Nagel RL (2004) Sickle-cell disease. Lancet 364: 1343–1360.
    1. Sparkenbaugh E, Pawlinski R (2013) Interplay between coagulation and vascular inflammation in sickle cell disease. Br J Haematol 162: 3–14.
    1. Wood KC, Hsu LL, Gladwin MT (2008) Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic Biol Med 44: 1506–1528.
    1. Lamarre Y, Hardy-Dessources MD, Romana M, Lalanne-Mistrih ML, Waltz X, et al. (In press) Relationships between systemic vascular resistance, blood rheology and nitric oxide in children with sickle cell anemia or sickle cell-hemoglobin C disease. Clin Hemorheol Microcirc.
    1. Lamarre Y, Romana M, Lemonne N, Hardy-Dessources MD, Tarer V, et al... (2013) Alpha thalassemia protects sickle cell anemia patients from macro-albuminuria through its effects on red blood cell rheological properties. Clin Hemorheol Microcirc.
    1. Lamarre Y, Romana M, Waltz X, Lalanne-Mistrih ML, Tressieres B, et al. (2012) Hemorheological risk factors of acute chest syndrome and painful vaso-occlusive crisis in children with sickle cell disease. Haematologica 97: 1641–1647.
    1. Nebor D, Bowers A, Hardy-Dessources MD, Knight-Madden J, Romana M, et al. (2011) Frequency of pain crises in sickle cell anemia and its relationship with the sympatho-vagal balance, blood viscosity and inflammation. Haematologica 96: 1589–1594.
    1. Steinberg MH (2005) Predicting clinical severity in sickle cell anaemia. Br J Haematol 129: 465–481.
    1. Owens AP 3rd, Mackman N (2011) Microparticles in hemostasis and thrombosis. Circ Res 108: 1284–1297.
    1. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, et al. (2003) Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 102: 2678–2683.
    1. van Beers EJ, Schaap MC, Berckmans RJ, Nieuwland R, Sturk A, et al. (2009) Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 94: 1513–1519.
    1. van Tits LJ, van Heerde WL, Landburg PP, Boderie MJ, Muskiet FA, et al. (2009) Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis. Biochem Biophys Res Commun 390: 161–164.
    1. Nebor D, Romana M, Santiago R, Vachiery N, Picot J, et al. (2013) Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children. Haematologica 98: 862–867.
    1. Gerotziafas GT, Van Dreden P, Chaari M, Galea V, Khaterchi A, et al. (2012) The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. Thromb Haemost 107: 1044–1052.
    1. Wolf P (1967) The nature and significance of platelet products in human plasma. Br J Haematol 13: 269–288.
    1. Westerman M, Pizzey A, Hirschman J, Cerino M, Weil-Weiner Y, et al. (2008) Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol 142: 126–135.
    1. Rank A, Nieuwland R, Crispin A, Grutzner S, Iberer M, et al. (2011) Clearance of platelet microparticles in vivo. Platelets 22: 111–116.
    1. Willekens FL, Werre JM, Kruijt JK, Roerdinkholder-Stoelwinder B, Groenen-Dopp YA, et al. (2005) Liver Kupffer cells rapidly remove red blood cell-derived vesicles from the circulation by scavenger receptors. Blood 105: 2141–2145.
    1. Ataga KI, Orringer EP (2003) Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 115: 721–728.
    1. Wun T, Paglieroni T, Rangaswami A, Franklin PH, Welborn J, et al. (1998) Platelet activation in patients with sickle cell disease. Br J Haematol 100: 741–749.
    1. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA (2005) Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 106: 1604–1611.
    1. Lentz BR (2003) Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res 42: 423–438.
    1. Camus SM, Gausseres B, Bonnin P, Loufrani L, Grimaud L, et al. (2012) Erythrocyte microparticles can induce kidney vaso-occlusions in a murine model of sickle cell disease. Blood 120: 5050–5058.
    1. Nouraie M, Lee JS, Zhang Y, Kanias T, Zhao X, et al. (2013) The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica 98: 464–472.
    1. Kato GJ, Gladwin MT, Steinberg MH (2007) Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 21: 37–47.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit